2013 NICE CG168 下肢静脉曲张的诊断和管理指南
2013-07-01 http://guidance.nice.org.uk/cg168
Varicose veins are dilated, often palpable subcutaneous veins with reversed blood flow. They aremost commonly found in the legs. Estimates of the prevalence of varicose veins vary. Visiblevaricose vei
2013 NICE CG168 下肢静脉曲张的诊断和管理指南
NICE clinical guideline 168-Varicose veins in the legs: the diagnosis and management of varicose veins
2013-07-01
Varicose veins are dilated, often palpable subcutaneous veins with reversed blood flow. They aremost commonly found in the legs. Estimates of the prevalence of varicose veins vary. Visiblevaricose veins in the lower limbs are estimated to affect at least a third of the population. Riskfactors for developing varicose veins are unclear, although prevalence rises with age and theyoften develop during pregnancy.In some people varicose veins are asymptomatic or cause only mild symptoms, but in othersthey cause pain, aching or itching and can have a significant effect on their quality of life.Varicose veins may become more severe over time and can lead to complications such aschanges in skin pigmentation, bleeding or venous ulceration. It is not known which people willdevelop more severe disease but it is estimated that 3–6% of people who have varicose veins intheir lifetime will develop venous ulcers.There are several options for the management of varicose veins, including:advice and reassuranceinterventional treatments (endothermal ablation, foam sclerotherapy and surgery)compression hosiery.In 2009/10 there were 35,659 varicose veins procedures carried out in the NHS. There is nodefinitive system for identifying which people will benefit the most from interventional treatmentand no established framework within the NHS for the diagnosis and management of varicoseveins. This has resulted in wide regional variations in the management of varicose veins in theUK. This guideline was developed with the aim of giving healthcare professionals guidance onthe diagnosis and management of varicose veins in the legs, in order to improve patient care andminimise disparities in care across the UK.The guideline will assume that prescribers will use a drug's summary of product characteristics toinform decisions made with individual patients.
链接失效了……
38